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transfémorale utilisant la prothèse Edwards SapienTM transcatheter heart
valve ou la prothèse Medtronic CoreValve® System chez des patients ayant une
sténose aortique à haut risque chirurgical
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IntroductionAortic stenosis is the most frequent valvular heart disease
in Western countries [1]. According to guidelines, surgical
aortic valve replacement (AVR) is the reference treatment
for patients with severe symptomatic aortic stenosis [2,3].
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peven years after the ﬁrst-in-man report [4], transcatheter
ortic valve implantation (TAVI) has emerged as a cred-ation 237
Summary
Objective.— We sought to describe the results of transfemoral aortic valve implantation using
either the SapienTM prosthesis or the CoreValve® System.
Background.— Results of transfemoral aortic valve implantation using both commercially avail-
able prostheses have rarely been studied.
Patients.— Of 236 patients at high-risk or with contraindications to surgery, consecutively
referred for transcatheter aortic valve implantation between October 2006 and June 2009, 83
were treated with transfemoral aortic valve implantation. The SapienTM was the only prosthe-
sis available until May 2008 and, since then, was used as the ﬁrst option, while the CoreValve®
System was used when contraindications to the SapienTM prosthesis were present.
Results.— Patients were aged 81± 9 years, 98% in New York Heart Association classes III/IV, with
predicted surgical mortalities of 26± 14% using the EuroSCORE and 15± 8% using the Society of
Thoracic Surgeons Predicted Risk of Mortality score. Seventy-two patients were treated with
the SapienTM prosthesis and 11 with the CoreValve® System. The valve was implanted in 94%
of the cases. Thirty-day mortality was 7%. Overall, 1- and 2-year survival rates were 78± 5%
and 71± 7%, respectively. Among patients treated with the SapienTM, the 1-year survival rate
was 67± 12% in the ﬁrst 20% of patients versus 86± 5% in the last 80% of patients (p = 0.02). In
univariate analysis, early experience was the only signiﬁcant predictor of 1-year mortality.
Conclusion.— Combining the use of the SapienTM and the CoreValve® prostheses increases the
number of patients who can be treated by transfemoral aortic valve implantation and provides
satisfactory results at 2 years in this high-risk population. The results are strongly inﬂuenced
by experience.
© 2010 Elsevier Masson SAS. All rights reserved.
Résumé
Introduction.— Les résultats d’une stratégie d’implantation valvulaire aortique transfémorale
utilisant l’une ou l’autre des deux prothèses commercialisées ont été peu décrits.
Objectif.— Décrire les résultats de l’implantation valvulaire aortique transfémorale utilisant
soit la prothèse SapienTM soit la prothèse CoreValve® System.
Patients.— Sur 236 patients ayant un haut risque ou une contre-indication chirurgicale, consé-
cutivement adressés entre octobre 2006 et juin 2009 pour implantation valvulaire aortique par
cathéter, 83 ont été traités par voie transfémorale. La prothèse SapienTM était la seule
disponible jusqu’en mai 2008. Après mai 2008, elle a été utilisée en première intention tan-
dis que la prothèse CoreValve® System a été utilisée en cas de contre-indication à la prothèse
SapienTM.
Résultats.— L’âge moyen des patients était de 81± 9 ans ; 98 % des patients étaient en classe
III ou IV de la New York Heart Association (NYHA) avec un score prédit de mortalité chirur-
gicale de 26± 14% selon l’EuroSCORE et 15± 8% selon le score de la Society of Thoracic
Surgeons. Soixante-douze patients ont été traités avec la prothèse SapienTM et 11 avec la
prothèse CoreValve® System. La prothèse a été implantée avec succès dans 94 % des cas. La
mortalité à 30 jours a été de 7%. Au total, les survies à un et à deux ans ont été respectivement
de 78± 5% et de 71± 7%. Parmi les patients traités avec la prothèse SapienTM, la survie à un
an a été de 67± 12% pour les premiers 20 % contre 86± 5% pour les derniers 80 % (p = 0,02). En
analyse univariée, l’expérience débutante était le seul facteur prédictif de mortalité à un an.
Conclusion.— L’utilisation combinée des prothèses SapienTM et CoreValve® augmente le nombre
de patients pouvant être traités par voie transfémorale et donne des résultats satisfaisantsble alternative therapy for patients with aortic stenosis
ho are considered at high-risk or with contraindications
or conventional AVR [5]. In most cases, procedures are
erformed via transfemoral (TF) or transapical approaches
2[
a
a
s
c
o
e
(
C
S
M
P
F
w
u
r
e
a
p
i
(
R
[
f
a
c
a
t
1
2
v
E
M
a
S
(
(
A
p
i
i
o
i
T
i
P
ﬂ
7
4
3
g
v
E
V
o
t
t
w
i
a
p
X
X
g
A
c
8
t
a
1
E
d
w
a
c
p
V
T
j
a
w
u
t
i
w
f
p
A
(
o
s
t
c
U
a
u
t
A
f
t
w38
6—8], but other approaches (e.g., subclavian, transiliac)
re being evaluated [9]. Among these possibilities, the TF
pproach is the most frequently used [10,11]. However, no
tudy reporting the results of TF TAVI using either of the two
ommercially available prostheses has been published.
The aim of this study was to describe the outcomes
f 83 patients consecutively treated with TF TAVI using
ither the Edwards SapienTM transcatheter heart valve (THV)
Edwards Lifesciences Inc., Irvine, CA, USA) or the Medtronic
oreValve® System (Medtronic Int. Trading, Tolochenaz,
witzerland).
ethods
atients
rom October 2006 to June 2009, all high-risk patients
ith severe symptomatic aortic stenosis evaluated for TAVI
nderwent multidisciplinary clinical evaluation, transtho-
acic echocardiography (TTE) and, if necessary, trans-
sophageal echocardiography (TEE), coronary angiography,
ortic and femoro-iliac angiography and multislice com-
uted tomography. The decision to perform TAVI was taken
n patients with contraindications to, or at high-risk for AVR
EuroSCORE≥20% or Society of Thoracic Surgeons Predicted
isk of Mortality [STS-PROM] ≥10%); life expectancy >1 year
12,13]; anatomy suitable for intervention [5]; and no need
or coronary artery bypass surgery.
The TF approach was considered as the ﬁrst option [10],
nd transapical, subclavian or transiliac in patients with
ontraindications to the TF approach, including: previous
ortofemoral bypass, bulky aortic atherosclerosis, porcelain
horacic aorta, a minimal luminal diameter <6mm for the
8 Fr sheaths, <7mm for the 22 Fr sheaths and <8mm for the
4 Fr sheaths, vessel kinking or severe angulation and severe
ascular calciﬁcation. From October 2006 to May 2008, the
dwards SapienTM THV was the only prosthesis used. From
ay 2008, the Medtronic CoreValve® System was used as an
lternative in cases of technical contraindications to the
apienTM THV:
1) femoro-iliac diameters too small, comprised between 6
and 7 or 8mm (according to the size of the prosthesis
to be implanted);
2) aortic annulus diameters too large, comprised between
25 and 27mm.
In patients with technical contraindications to any TAVI,
VR was reconsidered if the operative risk was not deemed
rohibitive. In patients who were too frail to undergo any
nvasive intervention or with comorbidities that clearly lim-
ted short-term life expectancy or precluded future quality
f life (mainly malignancies and cognitive disorders), a med-
cal treatment was decided upon.
ransfemoral transcatheter aortic valve
mplantation (TAVI)rocedures were performed under general anaesthesia, with
uoroscopic and TEE guidance. Patients received aspirin
5mg once daily and clopidogrel 75mg once daily for at least
days before the procedure, or a loading dose of clopidogrel
f
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00mg the day before the procedure. Heparin 70UI/kg was
iven intravenously before retrograde crossing of the aortic
alve.
dwards SapienTM transcatheter heart valve (THV)
ascular access was performed using two different meth-
ds over time: a percutaneous X-ray-guided puncture for
he ﬁrst 19 patients; then a surgical, view-guided punc-
ure for the last 53 patients. A femoral arterial 5 Fr sheath
as placed in the opposite groin to allow pressure mon-
toring and aortic angiograms through a Pigtail catheter,
nd a venous 8 Fr sheath to allow right ventricular rapid
acing.
-ray-guided puncture
-ray-guided puncture was performed under ﬂuoroscopic
uidance overlying the upper part of the bony femoral head.
6 Fr sheath (Terumo®, Tokyo, Japan) was placed in the
ommon femoral artery and after stepwise dilatation with
, 10 and 12 Fr dilatators, a 14 Fr sheath (Cook®, Blooming-
on, IN, USA) was placed to allow balloon dilatation of the
ortic valve. Thereafter, further stepwise dilatation with 16,
8, 20, 22 (±24) Fr dilatators was performed on an Amplatz
xtra Stiff wire (Cook®, Bjaeverstov, Denmark) before intro-
ucing the 22 or 24 Fr sheath on the same wire. The sheath
as pushed through the femoroiliac axis to the aorta, using
gentle twisting motion of the catheter under ﬂuoroscopic
ontrol. The artery was closed surgically at the end of the
rocedure.
iew-guided puncture
he common femoral artery was exposed and dissected free
ust below the inguinal ligament to gain access to a soft
rea of the artery. Proximal and distal control of the vessel
as obtained with vascular loops. After inspection and man-
al palpation of the artery, a puncture was made through
he skin and subcutaneous tissues 2 cm below the primary
ncision, providing a ﬁrm anchor for the sheath. The needle
as then inserted in the anterior vessel wall of the common
emoral artery avoiding important side-branches and bulky
laques. Then, the 22 or 24 Fr sheath was introduced on an
mplatz Extra Stiff wire or on an Extra Back Up Meier wire
Boston Scientiﬁc®, Miami, USA), under view control, with-
ut predilatation, and pushed to the descending aorta in the
ame fashion as described above.
Then, after retrograde crossing and predilatation of
he native valve, the prosthesis was pushed by a ﬂexible
atheter RetroFlexTM (Edwards Lifesciences®, Irvine, CA,
SA), positioned within the aortic valve using ﬂuoroscopic
nd TEE guidance, and then delivered by balloon inﬂation
nder rapid ventricular pacing.
After valve implantation, the sheath was withdrawn on
he stiff wire to the upper part of the external iliac artery.
n angiogram in an anteroposterior view was then per-
ormed to study the abdominal aorta, the common iliac, and
he ﬁrst 2 cm of the external iliac artery. Before complete
ithdrawal of the sheath, the access site in the common
emoral artery and the visible portion of the external iliac
rtery were inspected to detect arterial wall disruptions.
n the absence of any vascular complications, the common
emoral artery was clamped and repaired with polypropy-
ene sutures. After complete surgical vascular repair, a ﬁnal
ﬁ
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angiogram was performed using a pigtail introduced in the
opposite groin.
Medtronic CoreValve® System
Access and closure of the femoral artery were performed
percutaneously in all cases, using the Prostar XL® 10F
(Abbott Vascular® Devices Inc., Chicago, USA) with the pre-
closing technique. An 18 F sheath was inserted and the
procedure was similar to that with the Edwards SapienTM
prosthesis until aortic balloon predilatation. Then, the
prosthesis was pushed through the aorta to the left ven-
tricle. The outer sheath was slowly retracted, allowing the
deployment of the self-expanding prosthesis without rapid
pacing. During the progressive deployment of the prosthe-
sis, positioning could be corrected with gentle pull or push,
according to the ﬂuoroscopic and TEE guidance. Then, ﬁnal
retraction of the sheath led to complete delivery of the
prosthesis.
After valve implantation, conﬁrmation of the vascular
integrity was obtained as described above, and the femoral
artery was closed using the Prostar XL®.
After the procedure, patients were directed to the inten-
sive care unit for at least 48 hours. Physical examination was
performed every 6 hours to detect signs of limb ischemia.
Antiplatelet therapy consisted of aspirin 75mg and clopido-
grel 75mg daily. In case of surgical closure, inguinal drainage
was withdrawn after 48 hours if blood loss was <50 cc/24 h.
Standing was usually authorized after 48 hours. At discharge,
patients received aspirin plus clopidogrel for 3 to 6 months,
and then only one antiplatelet agent was continued. In
patients requiring long-term oral anticoagulation, only one
antiplatelet agent was used.
Follow-up
Hospital clinical and echocardiographic data were obtained
before discharge. All adverse events were prospectively
recorded. After the hospital phase, clinical and TTE follow-
up were obtained in all survivors at 1 to 3 months, 6 months,
1 year and then annually.
Outcomes
Outcomes were described according to the guidelines for
reporting mortality and morbidity after cardiac valve inter-
ventions [14].
Implantation success was deﬁned by valve implantation
in the correct position. Major vascular complications were
deﬁned as lesions requiring immediate or delayed vascular
interventions other than a simple arterial suture, or leading
to hospital death.
Statistical analysis
Data are expressed as mean± S.D., except for the length of
follow-up and length of stay in hospital, which are expressed
as median [25th—75th percentiles]. Categorical variables
were compared by the chi-square test or Fisher’s exact
test.
Late survival was analysed using Kaplan—Meier methods
and survival rates are given with their standard errors. To
assess experience a binary variable was used to separate the
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rst 20% (n = 15) from the last 80% (n = 57) of patients treated
ith the Edwards SapienTM THV. Analysis of the predictive
actors of late survival was performed by a univariate anal-
sis using a log-rank test. The 11 patients treated with the
edtronic CoreValve® System were excluded from this anal-
sis because their implantation began in May 2008. All tests
ere two-sided. A p value <0.05 was considered to indicate
statistically signiﬁcant difference. Statistical analysis was
erformed using statistical software Statistica version 5.0
Statsoft Inc., Tulsa, Oklahoma).
esults
atients
f the 236 patients who were at high-risk or had contraindi-
ations to AVR, 83 (35%) were treated by TF TAVI, 72 (30%)
sing the SapienTM THV and 11 (5%) the CoreValve® Sys-
em. Other patients who underwent TAVI were treated by
ransapical (n = 35, 15%) or subclavian/transiliac retroperi-
oneal (n = 1/2, 1%) access. Thirty (13%) patients were
eoriented toward conventional AVR, while 85 (36%) were
onsidered too frail, with a life expectancy too short to
ndergo any invasive intervention, or had technical con-
raindications to both TAVI and AVR, and were treated
edically.
The population studied here consisted of the 83 patients
ho were treated by TF TAVI. Its characteristics are detailed
n Table 1. Overall, the population was at high surgical risk.
ean age was 81± 9 years. Nearly all patients (98%) were
n New York Heart Association (NYHA) class III or IV. The
ajority had coronary artery disease and more than two
xtracardiac comorbidities. The SapienTM THV was used in 72
atients. Since May 2008, the CoreValve® System was chosen
n 11 patients because of contraindications to the SapienTM
HV: aortic annulus diameter too large (>25 and ≤27mm)
n six cases; femoro-iliac diameters too small (<7 or 8mm,
6mm) in ﬁve cases.
The expected operative mortality rates were 26± 14%
ccording to the EuroSCORE and 15± 8% according to the
TS score, with no signiﬁcant difference between patients
reated with the SapienTM THV and the CoreValve® Sys-
em. All patients (n = 8) with a EuroSCORE <20% and an STS
core <10% had contraindications to AVR, which were not
aken into account by these scores: severe respiratory fail-
re (n = 5), chest radiation sequellae (n = 1), intracerebral
neurysm (n = 1), morbid obesity (n = 1).
hirty-day outcomes
hirty-day outcomes are detailed in Table 2. Implantation
uccess was achieved in 78 (94%) patients. Technical fail-
res occurred with the SapienTM THV. Reasons for failure
ncluded inability to pass the iliac artery in three patients, to
ross the aortic valve with the prosthesis in one patient, and
aemopericardium in one patient due to perforation of the
eft ventricle by the wire, leading to intraprocedural death.
here was neither prosthesis embolization nor conversion to
n-pump surgical AVR. Immediately after implantation, par-
valvular leaks were frequent, but were grade≥III in only
hree (4%) patients.
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Table 1 Baseline characteristics of the study population.
Overall (n = 83) SapienTM THV
(n = 72)
CoreValve®
System
(n = 11)
P
Age (years, mean± S.D.) 81± 9 81± 9 79± 7 0.26
Women 39 (47) 36 (50) 3 (27) 0.20
New York Heart Association class
II 2 (2) 2 (3) 0 (0)
III 45 (54) 41 (57) 4 (36) 0.32
IV 36 (43) 29 (40) 7 (64)
Coronary artery disease 42 (51) 36 (50) 6 (55) 1
Previous myocardial infarction 11 (13) 9 (13) 2 (18) 0.63
Previous PCI 16 (19) 13 (18) 3 (27) 0.44
Previous CABG 18 (22) 17 (24) 1 (9) 0.44
Peripheral artery disease 23 (28) 20 (28) 3 (27) 1
Renal failure 26 (31) 21 (29) 5 (45) 0.3
Severe COPD 27 (33) 21 (29) 6 (26) 0.16
Cancer 27 (32) 20 (28) 7 (64) 0.04
Porcelain aorta 6 (7) 4 (6) 2 (18) 0.18
Two or more comorbidities 43 (52) 36 (50) 7 (64) 0.52
Aortic valve area (cm2) 0.69± 0.18 0.66± 0.16 0.89± 0.21 0.005
Aortic valve area (cm2/m2 BSA) 0.40± 0.10 0.38± 0.10 0.49± 0.10 0.009
Mean gradient (mmHg) 52± 16 53± 16 46± 13 0.13
Left ventricular ejection fraction (%) 52± 15 51± 15 58± 13 0.15
Aortic annulus diameter (mm) 23± 2 23± 2 24± 3 0.46
Bicuspid aortic valve 3 (4) 1 (1) 2 (18) 0.04
Minimal arterial diameter (mm) 7.8± 1 7.9± 1 7± 1 0.12
Logistic EuroSCORE (%), mean± S.D. (range) 26± 14 (3—90) 26± 15 (3—90) 23± 8 (9—37) 0.24
STS-PROM (%), mean± S.D. (range) 15± 8 (3—47) 15± 7 (3—35) 14± 15 (6—47) 0.93
Values are expressed as n (%) unless otherwise stated. BSA: body surface area; CABG: coronary artery bypass grafting; COPD: chronic
obstructive pulmonary disease; PCI: percutaneous coronary intervention; S.D.: standard deviation; STS-PROM: Society of Thoracic
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In one patient, emergent implantation of a second pros-
hesis into the ﬁrst one (‘‘valve after valve’’) was necessary,
ue to a massive intravalvular regurgitation induced by bal-
oon redilatation performed to treat severe paravalvular
eak.
The most frequent complications were vascular, overall
2%; all occurred with the SapienTM THV. There were four
liac dissections, of which one led to death 4 days after
urgical grafting, and six femoral injuries at the entry site.
ll of these complications were managed during the index
rocedure by surgical grafting (n = 6), stenting (n = 2) or com-
ined stenting and surgical grafting (n = 2). These vascular
omplications led to transfusion in seven patients. There
ere neither aortic dissections nor perforations.
Strokes occurred in 5% of patients, and led to disabling
equellae in one (1%) patient only. Complete atrioventricu-
ar block requiring pacemaker implantation occurred in 8% of
[
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dmplantation; THV: transcatheter heart valve.
he cases, and tended to be more frequent after CoreValve®
ystem implantation than after SapienTM THV (18% vs 7%,
= 0.23). One atrioventricular block occurred at 4 days, and
ne patient had a syncope 2 weeks after the procedure,
hich was also attributed to delayed complete atrioventric-
lar block.
Causes of deaths are detailed in Table 3. All-cause 30-day
ortality rate was 7% (n = 6).
ate outcomes
edian follow-up was 9 months (range: 1—36months)
3—15]. Ten deaths occurred after 30 days: three due to
xtracardiac causes (infections), four due to heart failure, of
hich two occurred in inoperable patients with one grade II
nd one grade III aortic regurgitations, and three were sud-
en, unexplained (Table 3). One- and 2-year survival rates
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Table 2 Thirty-day outcomes in the study population.
Overall
(n = 83)
SapienTM THV
(n = 72)
CoreValve®
System
(n = 11)
P
Implantation success 78 (94) 67 (93) 11 (100) 1
Aortic valve area (cm2) 1.7± 0.4 1.7± 0.4 1.9± 0.6 0.54
Aortic valve area (cm2/m2) 0.98± 0.25 0.96± 0.20 1.13± 0.40 0.43
Mean gradient (mmHg) 11± 4 12± 4 10± 6 0.5
Paravalvular aortic regurgitation
Grade 0 21 16 5
Grade I 41 37 4 0.3
Grade II 13 12 1
Grade III/IV 3 2 1
‘‘Valve after valve’’ 1 (1) 1 (10) 0 0.20
Femoral access/closure
All percutaneous 11 (14) 0 11 (100)
X-ray-guided puncture + surgical closure 21 (26) 21 (30) 0
View-guided puncture + surgical closure 51 (61) 51 (71) 0
Major vascular complications 10 (12) 10 (14) 0 0.34
Stroke 4 (5) 4 (6) 0 1
Tamponade 2 (2) 2 (3) 0 1
Heart blocka 7 (8) 5 (7) 2 (18) 0.23
Death per-procedure 2 (2) 2 (3) 0 0.09
30-day mortality 6 (7) 4 (6) 2 (18) 0.23
Length of hospital stay (days), median
[25th—75th percentiles]b
12 [9—16] 11 [7—12] 11 [9—16] 0.09
Values are expressed as n (%) or mean± S.D., unless otherwise stated. S.D.: standard deviation; THV: transcatheter heart valve.
a Requiring pacemaker implantation.
b From procedure to discharge.
were 78± 5% and 71± 7%, respectively (Fig. 1). In univariate
analysis, early experience was the only signiﬁcant predictor
of 1-year mortality: 1-year survival was 67± 12% in the 15
ﬁrst patients versus 86± 5% in the 57 last patients (p = 0.02)
treated with the Edwards SapienTM THV (Fig. 2).
Non-lethal valve-related events consisted only in one
case of endocarditis due to Streptococcus bovis that
occurred 5 months after the procedure and was successfully
treated medically, with no valve dysfunction. There was
no reintervention, haemolysis or permanent valve-related
impairment. No structural valve deterioration or dysfunc-
tion was observed. At last follow-up of the 66 survivors, 24
(36%) were in NYHA class I, 30 (46%) in class II, seven (11%)
in class III and ﬁve (7%) in class IV (Fig. 3). In the latter (four
men, 83± 10 years), reasons for remaining in class IV were
not due to a poor haemodynamic result of TAVI (aortic valve
area: 1.8± 0.1 cm2; mean gradient: 8± 3mmHg).Persistence of disabling symptoms was attributed to
severe pulmonary disease in three cases (one of whom had
idiopathic pulmonary hypertension), to depressed left ven-
tricular ejection fraction (35%) unchanged after TAVI, and to
left ventricular diastolic dysfunction in one case.
Figure 1. Two-year survival after transfemoral transcatheter
aortic valve implantation (TAVI). Kaplan—Meier survival in the
83 patients treated with transfemoral aortic valve implantation
(SapienTM transcatheter heart valve [THV] and CoreValve® System).
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Table 3 Causes of death in 83 patients treated with transfemoral aortic valve implantation.
Time/valve Days to death Cause of death
In-hospital
SapienTM 0 Haemopericardium (left ventricular perforation)Intraprocedural death
SapienTM 0 Hemopericardium (annular rupture) Intraprocedural death
CoreValve® 0 Massive aortic regurgitation, left ventricular failure
CoreValve® 0 Subaortic obstruction, left ventricular failure
SapienTM 1 Sudden, unexplained death
SapienTM 4 Iliac dissection Multiorgan failure after vascular surgery
Post-discharge
CoreValve® 46 Heart failure
SapienTM 79 Chronic renal failure, sudden unexplained death
SapienTM 82 Urinary infection
SapienTM 150 Sudden death
SapienTM 165 Pulmonary infection
SapienTM 222 Pulmonary infection (after neurosurgery)
SapienTM 263 Sudden, unexplained death
SapienTM 347 Heart failure (grade II paraprosthetic aortic regurgitationa)
SapienTM 421 Heart failure
SapienTM 445 Heart failure (grade III paraprosthetic aortic regurgitationa)
a As initially determined by transesophageal echocardiography and then evaluated by transthoracic echocardiography during follow-up.
Discussion
To the best of our knowledge, this prospective study is the
ﬁrst to report the outcomes of patients with severe symp-
tomatic aortic stenosis and high-risk for or contraindications
to AVR, after TF TAVI using either the SapienTM THV or the
CoreValve® System. Owing to the complementarities of the
devices, being able to use both of them increased the num-
ber of patients who could be treated with the TF approach.
Overall, late valve-related events were rare and clinical out-
Figure 2. One-year survival after transfemoral transcatheter aor-
tic valve implantation (TAVI) in the ﬁrst versus the last patients.
Kaplan—Meier survival in the ﬁrst 20% of patients treated with the
SapienTM transcatheter heart valve (THV) compared to the last 80%.
comes satisfactory in terms of survival as well as functional
improvement.
SapienTM transcatheter heart valve (THV) and
CoreValve® System
Besides their differences in terms of stent and prosthesis
materials, and implantation technique, both devices are not
strictly designed for the same anatomical proﬁles. As com-
pared with the 22/24 Fr sheaths necessary to accommodate
Figure 3. Functional status before and after transcatheter aortic
valve implantation (TAVI). Evolution of the New York Heart Associa-
tion (NYHA) functional class in patients between the preprocedure
condition and the last follow-up, after TAVI.
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the 23/26mm SapienTM THV, the 18 Fr sheath of the
CoreValve® System allows a larger number of patients to
be treated with the TF approach. This is of particular
importance because vascular access remains the main cause
for contraindications, failures and complications of the TF
approach. Similarly, patients with large (25—27mm) aortic
annulus diameters are eligible for the CoreValve® System
only, while, conversely, those with small (18—20mm) diam-
eters are eligible for the 23mm SapienTM THV only. Despite
the differences between the prostheses in terms of implan-
tation technique, both of which required a speciﬁc learning
period, the experience already acquired with the SapienTM
THV led to a shortening of this period when the CoreValve®
program was started in our centre.
Early outcome
Although predictive risk scores have limitations, with a trend
towards risk overestimation in the most severe patients
[15,16], the present 7% 30-day mortality clearly compares
favourably with the 26% operative mortality predicted by
the EuroSCORE and the 15% predicted by the STS score.
It is similar to the mortality reported by Piazza et al. in
a multicenter registry, using the CoreValve® System in 646
patients who, however, tended to have a lower risk pro-
ﬁle (mean EuroSCORE 23%) [7], and it is lower than the
11% mortality reported by Grube et al. in a single-centre
registry with the same device [6]. Our mortality is very sim-
ilar to the one recently reported by Webb et al. in 113
patients treated via the TF approach with the SapienTM THV
[11].
One-third (2/6) of early deaths occurred during the pro-
cedure itself, and all but one within the ﬁrst 24 hours
after performing the procedure. All deaths were due to
cardiovascular causes, and speciﬁc analysis of each death
suggested that most were linked to potential screening mis-
takes (e.g., aortic annular rupture, massive paravalvular
leak after TAVI in a bicuspid valve), and possibly might
have been avoided by experience. We already pointed
out the major clinical impact of this learning curve [10],
which is also shown by Webb et al. in their last series
where 30-day mortality fell from 12.3% in the initial half
of experience to 3.6% in the second half of experience
[11].
The main cause of severe morbidity when using the
SapienTM THV remained vascular complications, due to the
large diameters of the sheaths. However, they were sel-
dom life-threatening or led to secondary intervention, and
were mainly associated with a high need for transfusions.
As previously observed in a large series [7], this risk was
reduced dramatically by the use of the CoreValve® System,
compatible with 18 Fr sheaths.
The second most frequent complication was represented
by heart blocks necessitating pacemaker implantation.
Despite a lack of statistical power, their frequency seemed,
as previously observed, higher after CoreValve® System than
after SapienTM THV implantation [6—7]. Reasons for the dif-
ference between both prostheses have been analysed [17].
Particular attention should be paid to the delay in occur-
rence of conduction defects, up to 4 days in the present
series, implying a prolonged cardiac monitoring after the
procedure for optimal safety.
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Other non-fatal complications were very rare. In par-
icular, it should be noted that there was only one (1%)
troke leading to disabling sequellae, which seems quite
nexpected in this aged and high-risk population undergo-
ng retrograde cardiac catheterization with bulky devices.
urthermore, the risk of stroke in our study was comparable
ith previous surgical AVR series [18], despite our patients
ere at higher risk than patients selected for conventional
urgical AVR. Nevertheless, the risk of stroke remains a
ajor concern. To date, there is no convincing evidence that
t can be signiﬁcantly reduced by the transapical approach,
s compared to the TF approach. The current development
f lower-proﬁle and smaller catheters may further reduce
his risk in the near future.
ate outcomes
t follow-up with a median time of 9 months and a max-
mum of 3 years, mortality was due to non-cardiac causes
n at least one-third of the patients. As observed by Webb
t al. [11], the incidence of late adverse valve-related
vents was low. However, contrary to the latter, we did not
bserve severe gastrointestinal bleedings, which occurred in
atients with combined dual antiplatelet and warfarin ther-
py. In those patients requiring long-term anti-thrombotic
herapy, our practice was indeed to restrict antiplatelet
herapy to either aspirin or clopidogrel. As reported pre-
iously [19], aortic regurgitations more than mild were rare
ut grade≥II paravalvular leaks contributed, at least in part,
o left ventricular failure and late fatal outcomes in two
atients. Overall, the 1- and 2-year survival rates were con-
istent with those reported in the most recent TF series [11],
nd compared favourably with previous ones [6,20,21].
Most importantly, in this aged population, functional class
mprovement was dramatic and sustained after TAVI. While
8% of patients were in NYHA class III or IV before interven-
ion, 82% of survivors were in class I or II at last follow-up.
here was only one stroke leading to deﬁnitive sequellae in
patient who died from sepsis 3 months after intervention.
n most cases, persistence of NYHA class IV symptoms was
ssociated with concomitant severe pulmonary disease and
n others to multifactorial systolic or diastolic left ventric-
lar dysfunction. More accurate determination of clinical
redictors of poor functional results of TAVI will be neces-
ary to further improve the effectiveness of the screening
rocess.
earning curve
he direct impact on patients’ outcomes of a learning curve
eriod has already been observed and discussed in series
sing the SapienTM prosthesis via a TF approach alone, or
ombined TF and transapical approaches [10,11,20]. The
resent study leads to the same conclusions. The compar-
son of the survival curves of the ﬁrst and last patients
hows that excess mortality in the former group occurs
n the periprocedure period, with subsequently parallel
urves, thus conﬁrming the close inﬂuence of experience on
atients’ immediate outcomes, via the screening process,
he performance of the procedure and early postopera-
ive care. Indeed, this learning curve involves not only the
nterventional cardiologists and cardiovascular surgeons in
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harge of the procedure, but also imaging specialists, anaes-
hesiologists and all the members of the team participating
n the TAVI programme.
tudy limitations
his study reﬂects a single-centre experience, with a learn-
ng period, and involving a limited number of patients. It
lso reﬂects the current results of the TF approach for TAVI,
hich may change in the near future due to the expected
echnological evolutions and greater experience. In the
resent study, the SapienTM THV was the only prosthesis
vailable until May 2008, and since then, the CoreValve® Sys-
em has been used in case of contraindications to the former.
his strategy is somewhat arbitrary, but has increased the
umber of patients who could be treated by TF TAVI. No com-
arison between prostheses can be drawn from its results.
everal other strategies may be interesting to further assess
he respective places and results of the different approaches
nd prostheses available, e.g., using the CoreValve® System
n all patients, or the transapical approach with the SapienTM
HV in all patients, or combining the TF approach with the
oreValve® System and the transapical approach with the
apienTM THV.
onclusion and future directions
he availability of both SapienTM THV and CoreValve® Sys-
em increases the number of patients who can be treated by
F TAVI. Immediate results are strongly related to both the
uality of the screening and experience. Late functional and
urvival results are satisfactory and sustained. In the near
uture, expected technological improvements, with reduc-
ion of sheaths diameters, will allow routine performance of
ntirely percutaneous procedures under local anaesthesia,
nd then most probably further extend the place of the TF
pproach for TAVI, by increasing its feasibility, safety and
verall clinical beneﬁt.
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